A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efocipegtrutide (Primary)
Indications Non-alcoholic steatohepatitis
Focus Pharmacodynamics
Sponsors Hanmi Pharmaceutical

Most Recent Events

19 Feb 2025 Planned End Date changed from 10 Nov 2025 to 10 Nov 2026.
19 Feb 2025 Planned primary completion date changed from 11 May 2025 to 11 May 2026.
22 Jan 2025 Planned End Date changed from 10 Nov 2026 to 10 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight